文献速递慢性肾脏病

达贝泊汀α在非糖尿病晚期CKD患者中的随机对照试验

Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-04-03

PREDICT研究纳入491例非糖尿病晚期CKD患者(eGFR 8-20 ml/min/1.73m2),随机分至高血红蛋白组(目标11-13 g/dl)或低血红蛋白组(目标9-11 g/dl),使用达贝泊汀α治疗。主要肾脏复合终点在高、低血红蛋白组发生率分别为44%和48%(P=0.32),校正后HR 0.78(95%CI 0.60-1.03;P=0.08),心血管事件无显著差异。结论:靶向较高血红蛋白水平未改善肾脏结局。

要点

  • 非糖尿病晚期CKD患者中,达贝泊汀α靶向血红蛋白11-13 g/dl未显著改善肾脏复合终点。
  • 高血红蛋白组肾脏复合终点风险校正HR 0.78(95%CI 0.60-1.03;P=0.08),未达统计学显著性。
  • 两组心血管事件发生率相似(8% vs 7%,P=0.66)。

核心结论

  • 在非糖尿病晚期CKD患者中,使用达贝泊汀α靶向较高血红蛋白水平(11-13 g/dl)相比低水平(9-11 g/dl)未改善肾脏结局。

研究设计与样本

  • 多中心、随机、开放标签、平行组研究(PREDICT,NCT01581073),纳入491例非糖尿病CKD且eGFR 8-20 ml/min/1.73m2患者,最终高血红蛋白组239例、低血红蛋白组240例(排除12例)。

主要发现

  • 研究期间平均血红蛋白水平高组为11.2±1.1 g/dl,低组为10.0±0.9 g/dl,平均研究期73.5±29.7周。
  • 肾脏复合终点(开始维持透析、肾移植、eGFR≤6 ml/min/1.73m2、eGFR下降50%)在高组发生105例(44%),低组116例(48%)(log-rank P=0.32)。
  • 校正Cox模型显示高组vs低组风险比0.78(95%CI 0.60-1.03;P=0.08)。
  • 心血管事件在高组19例(8%),低组16例(7%),无显著组间差异(log-rank P=0.66)。

临床怎么用

  • 对于非糖尿病晚期CKD贫血患者,使用达贝泊汀α将血红蛋白目标定在11-13 g/dl并未显示肾脏获益,不支持以此高目标常规治疗。

局限性

  • 开放标签设计可能引入偏倚;主要终点未达统计学显著性;研究仅纳入日本非糖尿病患者,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Large, randomized, controlled trials targeting higher hemoglobin level with erythropoiesis-stimulating agents for Western patients with CKD showed harm. However, the effect of anemia correction using erythropoiesis-stimulating agents may differ between CKD subpopulations. The Prevention of ESKD by Darbepoetin Alfa in CKD Patients with Non-diabetic Kidney Disease study, a multicenter, randomized, open-label, parallel-group study, aimed to examine the effect of targeting hemoglobin levels of 11-13 g/dl using darbepoetin alfa with reference to a low-hemoglobin target of 9-11 g/dl on kidney outcome in patients with advanced CKD without diabetes in Japan. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We enrolled 491 patients with CKD without diabetes, and an eGFR of 8-20 ml/min per 1.73 m2. Of these 491 patients, 239 and 240 were ultimately assigned to the high- and low-hemoglobin groups, respectively (12 patients were excluded). The primary outcome was a kidney composite end point (starting maintenance dialysis, kidney transplantation, eGFR≤6 ml/min per 1.73 m2, and 50% reduction in eGFR). RESULTS: Mean hemoglobin levels were 11.2±1.1 and 10.0±0.9 g/dl in the high- and low-hemoglobin groups, respectively, during the mean study period of 73.5±29.7 weeks. The kidney composite end point occurred in 105 (44%) and 116 (48%) patients in the high- and low-hemoglobin groups, respectively (log-rank test; P=0.32). The adjusted Cox proportional hazards model showed that the hazard ratio for the high- versus low-hemoglobin group was 0.78 (95% confidence interval, 0.60 to 1.03; P=0.08). Cardiovascular events occurred in 19 (8%) and 16 (7%) patients in each group, respectively, with no significant between-group difference (log-rank test; P=0.66). CONCLUSIONS: Targeting a higher hemoglobin level (11-13 g/dl) with darbepoetin alfa did not improve kidney outcome compared with targeting a lower hemoglobin level (9-11 g/dl) in patients with advanced CKD without diabetes. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Prevention of ESKD by Darbepoetin Alfa in CKD Patients with Non-diabetic Kidney Disease (PREDICT), NCT01581073.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Hayashi T, Maruyama S, Nangaku M, et al. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. Clin J Am Soc Nephrol. 2020. PMID: 32245781. doi:10.2215/CJN.08900719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。